Indoco Remedies Limited has informed the Exchange about Credit Rating- Revision
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
ICRA has revised Indoco Remedies' credit ratings on 4th August 2025. The long-term ratings for term loans, cash credit, and unallocated facilities have been revised to [ICRA]A with a Negative outlook, while short-term fund-based and non-fund-based limits remain at [ICRA]A2+. ICRA stated this is a downgrade driven by weaker-than-expected revenues, shrinking operating profit margins, and worsening debt metrics in FY2025, with continued weakness in Q1 FY2026. The performance was hurt by supply disruptions from ongoing plant refurbishment under the company's master manufacturing plan and remediation work at its Goa facility, which particularly impacted export sales. ICRA also flagged that ongoing investments in the OTC toothpaste segment have pressured margins. The ratings continue to draw comfort from Indoco's strong domestic formulation business, geographic diversification, experienced management, and backward-integrated operations.
Negative for shareholders — the rating downgrade and negative outlook signal weakening financial health, likely leading to higher future borrowing costs and near-term pressure on the stock. Existing investors should monitor Q2 FY2026 results closely to see if operational recovery materialises.